Clinical Trial Team to Send Interim Report of COVID-19 Vaccine in January's End



Markus Wisnu Murti

  • Font:
  • Ukuran Font: - +
  • Illustration of COVID-19 vaccine. REUTERS/Dado Ruvic

    Illustration of COVID-19 vaccine. REUTERS/Dado Ruvic

    TEMPO.CO, JakartaThe COVID-19 vaccine clinical trial team planned to submit an interim report of the phase-3 trials of the vaccine candidates at the end of January 2021. The report will be the basis for the issuance of an emergency use authorization or EUA by the Food and Drug Monitoring Agency (BPOM).

    “At the end of January, we will send an interim report to Bio Farma (pharmaceutical firm),” said clinical trial team head Kusnandi Rusmil in a webinar regarding the pandemic and global vaccines organized by the Padjadjaran University and the Indonesia Chamber of Commerce and Industry (Kadin) on Monday, January 4, 2021.

    Indonesia is currently conducting the phase-3 clinical trials of the Sinovac vaccine produced in collaboration with Chinese pharmaceutical company Sinovac Biotech Ltd.

    Since the clinical trials have not been completed, Kusnandi explained the effectiveness of the COVID-19 vaccine candidate remained unknown. However, he ensured that vaccination would not cause harmful effects.

    He also believed that the vaccination program in Indonesia would run smoothly as the country had vast experience in conducting various types of immunization.

    Read: Indonesia to Kick Off COVID-19 Vaccination Program Next Week